Elobixibat is a first-in-class compound under investigation for treatment of chronic idiopathic constipation (CIC), and for irritable bowel syndrome with constipation (IBS-C). It works by reducing bile acid absorption in the small intestine. This stimulates bowel movements by increasing fluid secretions and motility in the colon.
In Phase 2b clinical trials, elobixibat (formerly A3309) has been evaluated in patients in the U.S. and Europe for the treatment of CIC. The studies demonstrated clinically meaningful, statistically significant, and dose-dependent improvements. These included increased stool frequency and improved constipation-related symptoms such as straining, stool consistency, and bloating maintained over 8 weeks of treatment.
May 27, 2014 —An article published in the journal Therapeutic Advances in Gastroenterology reviewed data that examined the mechanisms by which bile acids can affect symptoms in chronic idiopathic constipation (CIC) and the role of the drug elobixibat in managing these symptoms. Bile acids are digestive juices that have a stimulating effect in the colon. Elobixibat reduces bile acid absorption in the small intestine. This stimulates bowel movements by increasing fluid secretions and motility in the colon.
The authors concluded that published research shows that elobixibat significantly affects the symptoms of CIC, with minimal and tolerable side effects.
May 2, 2013 — Elobixibat has entered Phase 3 trials for the CIC indication. There will be two studies which will be conducted at close to 200 sites around the world.
Elobixibat is being developed by Ferring Pharmaceuticals under a licensing agreement with Albireo AB. The agreement gives Ferring rights to market the product globally with the exception of Japan and a small number of Asian markets.